Robin Shane Readnour

Insider Reports History

Entity
Individual
Location
3835 Cleghorn Avenue, Suite 300, Nashville, TN
Signature
/s/ Eric Easom, Attorney-in-Fact for Robin Shane Readnour
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Robin Shane Readnour:

Stock Role Class Num Shares Value Price $ Report Date Ownership
AN2 Therapeutics, Inc. Director Common Stock 653K $975K $1.49 Dec 19, 2024 Indirect
AN2 Therapeutics, Inc. Director Common Stock 9.08K $13.6K $1.49 Dec 19, 2024 Direct
AN2 Therapeutics, Inc. Director Stock Option (Right to Buy) 64.5K Jun 19, 2024 Direct

Insider Reports Filed by Robin Shane Readnour

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ANTX AN2 Therapeutics, Inc. Dec 19, 2024 1 $0 4 Dec 23, 2024 Director
ANTX AN2 Therapeutics, Inc. Dec 6, 2024 6 $86.7K 4 Dec 10, 2024 Director
ANTX AN2 Therapeutics, Inc. Nov 26, 2024 4 $106K 4 Nov 27, 2024 Director
ANTX AN2 Therapeutics, Inc. Nov 19, 2024 4 $213K 4 Nov 21, 2024 Director
ANTX AN2 Therapeutics, Inc. Jun 19, 2024 1 $0 4 Jun 21, 2024 Director
ANTX AN2 Therapeutics, Inc. Jan 12, 2024 2 -$31.2K 4 Jan 17, 2024 Director
ANTX AN2 Therapeutics, Inc. Jan 10, 2024 2 -$80.4K 4 Jan 12, 2024 Director
ANTX AN2 Therapeutics, Inc. Jun 7, 2023 1 $0 4 Jun 9, 2023 Director
ANTX AN2 Therapeutics, Inc. May 12, 2022 1 $0 4 May 16, 2022 Director
ANTX AN2 Therapeutics, Inc. Mar 29, 2022 10 $2.3M 4 Mar 31, 2022 Director
ANTX AN2 Therapeutics, Inc. Mar 24, 2022 0 $0 3 Mar 24, 2022 Director